Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1000-0.0500 (-2.33%)
At close: 12:58PM EST
Advertisement

Evaxion Biotech A/S

Dr. Neergaards Vej
5th Floor
Horsholm 2970
Denmark
45 53 53 18 50
https://www.evaxion-biotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Dr. Niels Iversen Moeller M.D.Co-Founder, VP of Bus. & Director268kN/A1979
Mr. Andreas Holm MattssonCo-Founder and Chief AI & Culture Officer290kN/A1976
Dr. Birgitte Rono Ph.D.Chief Scientific Officer309kN/A1976
Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D.Chief Medical Officer532kN/A1968
Dr. Per NorlenChief Exec. OfficerN/AN/A1970
Mr. Bo Lokke KarmarkChief Financial OfficerN/AN/A1965
Mr. Jesper Nyegaard NissenChief Operating OfficerN/AN/A1970
Dr. Jürgen Langhärig EMBA, Ph.D.Head of Bus. Devel. & Member of Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Corporate Governance

Evaxion Biotech A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement